Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo

International Journal of Oncology

Volumn 46, Issue 6, 2015, Pages 2419-2430

  Fujita, Koji ^a   Iwama, Hisakazu ^b   Sakamoto, Teppei ^a   Okura, Ryoichi ^a   Kobayashi, Kiyoyuki ^a   Takano, Jitsuko ^a   Katsura, Akiko ^a   Tatsuta, Miwa ^a   Maeda, Emiko ^a   Mimura, Shima ^a   Nomura, Takako ^a   Tani, Joji ^a   Miyoshi, Hisaaki ^a   Morishita, Asahiro ^a   Yoneyama, Hirohito ^a   Yamana, Yuka ^a   Himoto, Takashi ^a   Okano, Keiichi ^b   Suzuki, Yasuyuki ^b   Niki, Toshiro ^b   Hirashima, Mitsuomi ^b   Masaki, Tsutomu ^a   more..

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; DYRK1A; Galectin 9; Hepatocellular carcinoma; miR 1246

Indexed keywords

CASPASE 4; CASPASE 8; CASPASE 9; ECALECTIN; MICRORNA; MICRORNA 1227 5P; MICRORNA 1237 5P; MICRORNA 1246; MICRORNA 142 5P; MICRORNA 1908; MICRORNA 1909 3P; MICRORNA 3180; MICRORNA 3621; MICRORNA 3940 5P; MICRORNA 3960; MICRORNA 4257; MICRORNA 4289; MICRORNA 4294; MICRORNA 4459; MICRORNA 4463; MICRORNA 4485; MICRORNA 4530; MICRORNA 4749 5P; MICRORNA 4763 3P; MICRORNA 489; MICRORNA 6075; MICRORNA 6076; MICRORNA 6131; MICRORNA 642B 3P; PROTEIN TIM 3; UNCLASSIFIED DRUG; DYRK KINASE; GALECTIN; LGALS9 PROTEIN, HUMAN; MIRN1246 MICRORNA, HUMAN; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HEPATOCELLULAR CARCINOMA CELL LINE; IN VITRO STUDY; IN VIVO STUDY; INTERMEDIATE FILAMENT; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; TUNEL ASSAY; UPREGULATION; WESTERN BLOTTING; WST-8 ASSAY; ANIMAL; CANCER TRANSPLANTATION; CELL CYCLE; GENETICS; HUMAN; LIVER TUMOR; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GALECTINS; HUMANS; LIVER NEOPLASMS; MICE; MICRORNAS; NEOPLASM TRANSPLANTATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES;

EID: 84928537942     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2941     Document Type: Article

References (37)

1. Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
2. Meza-Junco J, Montano-Loza AJ, Liu DM, Sawyer MB, Bain VG, Ma M and Owen R: Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev 38: 54-62, 2012.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
4. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, et al: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol 57: 821-829, 2012.
5. Wada J, Ota K, Kumar A, Wallner EI and Kanwar YS: Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J Clin Invest 99: 2452-2461, 1997.
6. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, Stevens RL and Hirashima M: Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 273: 16976-16984, 1998.
7. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6: 1245-1252, 2005.
8. Rabinovich GA, Liu FT, Hirashima M and Anderson A: An emerging role for galectins in tuning the immune response: Lessons from experimental models of inflammatory disease, autoimmunity and cancer. Scand J Immunol 66: 143-158, 2007.
9. + T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 181: 7660-7669, 2008.
10. Fujihara S, Mori H, Kobara H, Rafiq K, Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy. Recent Pat Endocr Metab Immune Drug Discov 7: 130-137, 2013.
11. Wiersma VR, de Bruyn M, Helfrich W and Bremer E: Therapeutic potential of Galectin-9 in human disease. Med Res Rev 33 (Suppl 1): E102-E126, 2013.
12. Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima M, et al: Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res 8: 994-1001, 2010.
13. Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N, et al: Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia 24: 843-850, 2010.
14. Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M: Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 99: 809-816, 2002.
15. Zhang ZY, Dong JH, Chen YW, Wang XQ, Li CH, Wang J, Wang GQ, Li HL and Wang XD: Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac J Cancer Prev 13: 2503-2509, 2012.
16. Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G, et al: Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56: 1342-1351, 2012.
17. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, Shoji H and Nakamura T: Development of highly stable galectins: Truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett 579: 2058-2064, 2005.
18. Nishikawa T, Nakajima T, Moriguchi M, Jo M, Sekoguchi S, Ishii M, Takashima H, Katagishi T, Kimura H, Minami M, et al: A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins. J Hepatol 44: 1074-1082, 2006.
19. Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N, Nakamura T and Hirashima M: Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 170: 3631-3636, 2003.
20. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM and Green DR: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by over-expression of Bcl-2 and Abl. J Exp Med 182: 1545-1556, 1995.
21. Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al: The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 11: 549-560, 2012.
22. Kobayashi M, Kato K, Iwama H, Fujihara S, Nishiyama N, Mimura S, Toyota Y, Nomura T, Nomura K, Tani J, et al: Antitumor effect of metformin in esophageal cancer: In vitro study. Int J Oncol 42: 517-524, 2013.
23. Schutte B, Henfling M, Kölgen W, Bouman M, Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et al: Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 297: 11-26, 2004.
24. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, et al: Committee of the National Cancer Research Institute: Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577, 2010.
25. Tamura T, Fujita F, Tanimoto M, Koike M, Suzuki A, Fujita M, Horikiri Y, Sakamoto Y, Suzuki T and Yoshino H: Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice. J Control Release 80: 295-307, 2002.
26. Miyoshi H, Kato K, Iwama H, Maeda E, Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, et al: Effect of the antidiabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol 45: 322-332, 2014.
27. Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193, 2003.
28. Rao RV, Ellerby HM and Bredesen DE: Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 11: 372-380, 2004.
29. Zhang Y, Liao JM, Zeng SX and Lu H: p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Rep 12: 811-817, 2011.
30. Asghar U and Meyer T: Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 56: 686-695, 2012.
31. Callegari E, Elamin BK, Sabbioni S, Gramantieri L and Negrini M: Role of microRNAs in hepatocellular carcinoma: A clinical perspective. Onco Targets Ther 6: 1167-1178, 2013.
32. Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, Takeshita K, Niki T, Tominaga A, Yamauchi A and Hirashima M: Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 18: 735-744, 2008.
33. Kerr TA, Korenblat KM and Davidson NO: MicroRNAs and liver disease. Transl Res 157: 241-252, 2011.
34. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
35. Kushibiki T, Hirasawa T, Okawa S and Ishihara M: Regulation of miRNA expression by low-level laser therapy (LLLT) and photodynamic therapy (PDT). Int J Mol Sci 14: 13542-13558, 2013.
36. Bach D, Fuereder J, Karbiener M, Scheideler M, Ress AL, Neureiter D, Kemmerling R, Dietze O, Wiederstein M, Berr F, et al: Comprehensive analysis of alterations in the miRNome in response to photodynamic treatment. J Photochem Photobiol B 120: 74-81, 2013.
37. Deng L, Ren Z, Jia Q, Wu W, Shen H and Wang Y: Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. BMC Cancer 13: 363, 2013.